The present invention relates to a method for treating a subject suffering from a cancer comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of NETs.
By in vitro experiments, inventors have demonstrated that inhibiting the formation of NETs with a PAD4 inhibitor or digesting the NET-DNA scaffold with DNase I during PMA-induced NET formation overcame the chemoresistance induced by the NET CM in vitro.
They have also generated data in vivo and shown that targeting of NETs with either a PAD4 inhibitor or DNase I enhanced chemotherapy efficacy. PAD4 inhibition and DNase I treatment not only eliminated NETs in the metastatic lungs and in the plasma, but also reduced neutrophil recruitment to the lungs.